Détail - canceropole-wordpress

Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium.

Marton C, Clémenceau B, Dachy G, Demerle C, Derenne S, Ferrand C, Giverne C, Latouche JB, Lemée L, Martinet J, Bonig H, Bensoussan D, Chabannon C, Köhl U, Deschamps M, De Vos J, Diana JS, Dougé A, Forcade E, Galaine J, Thiant S, Galy A, Larghero J, Reppel L, Viel S, Boyer O, Yakoub-Agha I

Bone Marrow Transplant. 2025 05 29;:

[European Pharmacovigilance of Advanced Therapy Medicinal Products].

Petitpain N, Prontskus V, Gauthier M, Loutterbach L, Pochon C, Dalle JH, Bensoussan D

Ann Pharm Fr. 2025 02 27;:

Identification of the conditions and minimum requirements necessary for the release of autologous fresh CAR T-cell products under hospital exemption: a position paper from the WP-bioproduction of the UNITC consortium.

Boyer O, Bensoussan D, Bönig H, Chabannon C, Clémenceau B, Cuffel A, Dachy G, de Vos J, Derenne S, Diana JS, Dougé A, Deramoudt L, Ferrand C, Forcade E, Galaine J, Galy A, Giverne C, Martinet J, Marton C, Larghero J, Reppel L, Viel S, Yakoub-Agha I, Deschamps M

Bone Marrow Transplant. 2025 01 25;:

Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context.

Wang V, Savoldo B, Guimaraes JA, Dotti G, Reppel L, Bensoussan D

Front Immunol. 2025 01 15;15:1527648

Deciphering Natural Killer Cell Cytotoxicity Against Medulloblastoma in vitro and in vivo: Implications for Immunotherapy.

Gauthier M, Pierson J, Moulin D, Mouginot M, Bourguignon V, Rhalloussi W, Vincourt JB, Dumas D, Bensoussan D, Chastagner P, Boura C, Decot V

Immunotargets Ther. 2024 06 26;13:319-333

On behalf of the SFGM-TC: Real-life use of third-party virus-specific T-cell transfer in immunocompromised transplanted patients.

Leroyer EH, Petitpain N, Morisset S, Neven B, Castelle M, Winter S, Souchet L, Morel V, Le Cann M, Fahd M, Yacouben K, Mechinaud F, Ouachée-Chardin M, Renard C, Wallet HL, Angoso M, Jubert C, Chevallier P, Léger A, Rialland F, Dhedin N, Robin C, Maury S, Beckerich F, Beauvais D, Cluzeau T, Loschi M, Fernster A, Bittencourt MC, Cravat M, Bilger K, Clément L, Decot V, Gauthier M, Legendre A, Larghero J, Ouedrani A, Martin-Blondel G, Pochon C, Reppel L, Rouard H, Nguyen-Quoc S, Dalle JH, D'Aveni M, Bensoussan D

Hemasphere. 2024 01;8(1):e40

[Organizational and budgetary impacts of the implementation of CAR-T cell therapies in a French academic hospital].

Fleta L, Gauthier M, Lider P, Campidelli A, Demoré B, Bensoussan D, Reppel L

Bull Cancer. 2023 09 5;:

Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial.

Pochon C, Laroye C, Kimmoun A, Reppel L, Dhuyser A, Rousseau H, Gauthier M, Petitpain N, Chabot JF, Valentin S, de Carvalho Bittencourt M, Peres M, Aarnink A, Decot V, Bensoussan D, Gibot S

Front Med (Lausanne). 2023 08 29;10:1224865

Scale-Up of Academic Mesenchymal Stromal Cell Production.

Laroye C, Gauthier M, Morello J, Charif N, Cannard VL, Bonnet C, Lozniewski A, Tchirkov A, De Isla N, Decot V, Reppel L, Bensoussan D

J Clin Med. 2023 06 30;12(13):

A French single-center experience on allogeneic stem cell transplant cryopreservation during severe acute respiratory syndrome coronavirus 2 pandemic.

Laroye C, Thilly N, Gauthier M, Luc A, Latger-Cannard V, Eschwege V, Bensoussan D, Pochon C, Campidelli A, Rubio MT, D'Aveni M, Decot V

Cytotherapy. 2023 04 17;:

Pre-Professional International Mobility of European Pharmacy Students-A French Example.

Varbanov M, Bensoussan D, Devocelle M

Pharmacy (Basel). 2023 03 20;11(2):

Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input.

Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D

Cancers (Basel). 2023 02 4;15(4):

Wharton's jelly-derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation.

Pochon C, Notarantonio AB, Laroye C, Reppel L, Bensoussan D, Bertrand A, Rubio MT, D'Aveni M

J Cell Mol Med. 2022 Jan 28;:

Adverse Mechanical Ventilation and Pneumococcal Pneumonia Induce Immune and Mitochondrial Dysfunctions Mitigated by Mesenchymal Stem Cells in Rabbits.

Blot M, Jacquier M, Pauchard LA, Rebaud C, Marlin C, Hamelle C, Bataille A, Croisier D, Thomas C, Jalil A, Mirfendereski H, Piroth L, Chavanet P, Bensoussan D, Laroye C, Reppel L, Charles PE

Anesthesiology. 2021 Dec 29;:

Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC).

Rafii H, Ionescu I, Ruggeri A, Garnier F, Ballot C, Bensoussan D, Chabannon C, Dazey B, De Vos J, Gautier E, Giraud C, Larghero J, Cras A, Mialou V, Persoons V, Pouthier F, Thibert JB, Dalle JH, Michel G, Sinayoko M, Kenzey C, Volt F, Rocha V, Bay JO, Rubio MT, Robin M, Faucher C, Marry E, Gluckman E

Bone Marrow Transplant. 2021 Oct 7;:

Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC).

Rafii H, Garnier F, Ruggeri A, Ionescu I, Ballot C, Bensoussan D, Chabannon C, Dazey B, De Vos J, Gautier E, Giraud C, Larghero J, Cras A, Mialou V, Persoons V, Pouthier F, Thibert JB, Dalle JH, Michel G, Kenzey C, Volt F, Rocha V, Bay JO, Rubio MT, Faucher C, Marry E, Gluckman E

Bone Marrow Transplant. 2021 May 14;:

Natural Killer cells and monoclonal antibodies: two partners for successful antibody dependent cytotoxicity against tumor cells.

Gauthier M, Laroye C, Bensoussan D, Boura C, Decot V

Crit Rev Oncol Hematol. 2021 Feb 16;:103261

Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19.

Laroye C, Gibot S, Huselstein C, Bensoussan D

Stem Cells Transl Med. 2020 Aug 18;:

Are the Immune Properties of Mesenchymal Stem Cells from Wharton's Jelly Maintained during Chondrogenic Differentiation?

Voisin C, Cauchois G, Reppel L, Laroye C, Louarn L, Schenowitz C, Sonon P, Poras I, Wang V, D Carosella E, Benkirane-Jessel N, Moreau P, Rouas-Freiss N, Bensoussan D, Huselstein C

J Clin Med. 2020 Feb 4;9(2):

Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton's Jelly, an Extraembryonic Source.

Laroye C, Gauthier M, Antonot H, Decot V, Reppel L, Bensoussan D

J Clin Med. 2019 Dec 14;8(12):

Bone marrow vs Wharton's jelly mesenchymal stem cells in experimental sepsis: a comparative study.

Laroye C, Boufenzer A, Jolly L, Cunat L, Alauzet C, Merlin JL, Yguel C, Bensoussan D, Reppel L, Gibot S

Stem Cell Res Ther. 2019 Jun 27;10(1):192

Clinical-grade mesenchymal stem cells derived from umbilical cord improve septic shock in pigs.

Laroye C, Lemarié J, Boufenzer A, Labroca P, Cunat L, Alauzet C, Groubatch F, Cailac C, Jolly L, Bensoussan D, Reppel L, Gibot S

Intensive Care Med Exp. 2018 Aug 8;6(1):24

Adenovirus-specific T-lymphocyte efficacy in the presence of methylprednisolone: An in vitro study.

Campidelli A, Qian C, Laroye C, Decot V, Reppel L, D'aveni M, Bensoussan D

Cytotherapy. 2018 Apr;20(4):524-531

Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.

Qian C, Wang Y, Reppel L, D'aveni M, Campidelli A, Decot V, Bensoussan D

Bone Marrow Transplant.. 2018 Feb;53(2):114-122

[Treatment by stem cell therapy of erectile dysfunction of diabetic origin: State of the art].

El Osta R, Decot V, Bensoussan D, Stoltz JF, Eschwege P, Hubert J

Prog. Urol.. 2018 Feb;28(2):74-84

Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.

Xiong Y, Mouginot M, Reppel L, Qian C, Stoltz JF, Bensoussan D, Decot V

Immunol. Res.. 2017 Oct;:

Mesenchymal Stromal/Stem Cells: A New Treatment For Sepsis And Septic Shock?

Laroye C, Gibot S, Reppel L, Bensoussan D

Stem Cells. 2017 Aug;:

Umbilical cord-derived mesenchymal stromal cells: predictive obstetric factors for cell proliferation and chondrogenic differentiation.

Avercenc-Léger L, Guerci P, Virion JM, Cauchois G, Hupont S, Rahouadj R, Magdalou J, Stoltz JF, Bensoussan D, Huselstein C, Reppel L

Stem Cell Res Ther. 2017 Jul;8(1):161

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.

Qian C, Campidelli A, Wang Y, Cai H, Venard V, Jeulin H, Dalle JH, Pochon C, D'aveni M, Bruno B, Paillard C, Vigouroux S, Jubert C, Ceballos P, Marie-Cardine A, Galambrun C, Cholle C, Clerc Urmes I, Petitpain N, De Carvalho Bittencourt M, Decot V, Reppel L, Salmon A, Clement L, Bensoussan D

J Hematol Oncol. 2017 May;10(1):102

Cryopreservation as a way to maintain extracorporeal photopheresis regimen for GvHD treatment while circumventing patient temporary inability to undergo apheresis.

Pochon C, Reppel L, Halle P, Zang A, Clément L, Michel D, Perrot A, Roth-Guépin G, Detrait M, Kanold J, Rouel N, Donzé B, Décot V, Mathieu-Nafissi S, Merlin E, Bensoussan D

Bone Marrow Transplant.. 2017 Jan;52(1):167-170

Mechanobiology of mesenchymal stem cells: Which interest for cell-based treatment?

Huselstein C, Rahouadj R, de Isla N, Bensoussan D, Stoltz JF, Li YP

Biomed Mater Eng. 2017 ;28(s1):S47-S56

Mesenchymal Stem Cells Derived from Human Bone Marrow and Adipose Tissue Maintain Their Immunosuppressive Properties After Chondrogenic Differentiation: Role of HLA-G.

Du WJ, Reppel L, Leger L, Schenowitz C, Huselstein C, Bensoussan D, Carosella ED, Han ZC, Rouas-Freiss N

Stem Cells Dev.. 2016 Oct;25(19):1454-69

Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-γ Immunomagnetic Selection.

Qian C, Wang Y, Cai H, Laroye C, De Carvalho Bittencourt M, Clement L, Stoltz JF, Decot V, Reppel L, Bensoussan D

J. Immunother.. 2016 Jan;39(1):27-35

Stem cells and vascular regenerative medicine: A mini review.

Stoltz JF, Bensoussan D, De Isla N, Zhang L, Han Z, Magdalou J, Huselstein C, Ye JS, Leballe B, Decot V, Reppel L

Clin. Hemorheol. Microcirc.. 2016 ;64(4):613-633

Chondrogenic induction of mesenchymal stromal/stem cells from Wharton's jelly embedded in alginate hydrogel and without added growth factor: an alternative stem cell source for cartilage tissue engineering.

Reppel L, Schiavi J, Charif N, Leger L, Yu H, Pinzano A, Henrionnet C, Stoltz JF, Bensoussan D, Huselstein C

Stem Cell Res Ther. 2015 Dec;6:260

Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.

Xiong Y, Bensoussan D, Decot V

Transfus Med Rev. 2015 Jul 10. pii: S0887-7963(15)00073-5

Human monocyte response to S-nitrosoglutathione-loaded nanoparticles: uptake, viability, and transcriptome.

Safar R, Ronzani C, Diab R, Chevrier J, Bensoussan D, Grandemange S, Le Faou A, Rihn BH, Joubert O

Mol. Pharm.. 2015 Feb;12(2):554-61

Percutaneous autologous bone marrow injection for treatment of delayed and non-union of long bone: a retrospective study of 45 cases.

Gross JB, Diligent J, Bensoussan D, Galois L, Stoltz JF, Mainard D

Biomed Mater Eng. 2015;25(1 Suppl):187-97

Stem cells and applications: a survey.

Stoltz JF, Bensoussan D, Zhang L, Decot V, De Isla N, Li YP, Huselstein C, Benkirane-Jessel N, Li N, Reppel L, He Y, Li YY

Biomed Mater Eng. 2015;25(1 Suppl):3-26

Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century.

Stoltz JF, de Isla N, Li YP, Bensoussan D, Zhang L, Huselstein C, Chen Y, Decot V, Magdalou J, Li N, Reppel L, He Y

Stem Cells Int. 2015;2015:734731

Validation of a single-platform method for hematopoietic CD34+ stem cells enumeration according to accreditation procedure.

Massin F, Huili C, Decot V, Stoltz JF, Bensoussan D, Latger-Cannard V

Biomed Mater Eng. 2015;25(1 Suppl):27-39

Hypoxic Culture Conditions for Mesenchymal Stromal/Stem Cells from Wharton's Jelly: A Critical Parameter to Consider in a Therapeutic Context.

Reppel L, Margossian T, Yaghi L, Moreau P, Mercier N, Leger L, Hupont S, Stoltz JF, Bensoussan D, Huselstein C

Curr Stem Cell Res Ther. 2014 Jul;9(4):306-18.

Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.

Wang Y, Aissi-Rothe L, Virion JM, De Carvalho Bittencourt M, Ulas N, Audonnet S, Salmon A, Clement L, Venard V, Jeulin H, Stoltz JF, Decot V, Bensoussan D

Cytotherapy. 2014 Jan;16(1):122-34

Donor's age dependent proliferation decrease of human bone marrow mesenchymal stem cells is linked to diminished clonogenicity.

Li Y, Charif N, Mainard D, Bensoussan D, Stoltz JF, de Isla N

Biomed Mater Eng. 2014;24(1 Suppl):47-52

Hypoxic culture conditions for Mesenchymal Stromal/Stem Cells from Wharton's jelly: a critical parameter to consider in a therapeutic context.

Reppel L, Margossian T, Yaghi L, Moreau P, Mercier N, Leger L, Hupont S, Stoltz JF, Bensoussan D, Huselstein C

Curr Stem Cell Res Ther. 2014;9(4):306-18.

Human stem cells and articular cartilage tissue engineering.

Stoltz JF, Huselstein C, Schiavi J, Li YY, Bensoussan D, Decot V, De Isla N

Curr Pharm Biotechnol. 2012 Dec;13(15):2682-91.

Antiviral adoptive immunotherapy after allogeneic hematopoietic stem cell.

Aissi-Rothe L, Wang YY, Decot V, Stoltz JF, Bensoussan D

. 2012 Nov-dec;16(6):342-55.

Residual viability is a predictor of the perfusion enhancement obtained with the cell therapy of chronic myocardial infarction: a pilot multimodal imaging study.

Maureira P, Tran N, Djaballah W, Angioi M, Bensoussan D, Didot N, Fay R, Sadoul N, Villemot JP, Marie PY

Clin Nucl Med. 2012 Aug;37(8):738-42

Effect of dynamic loading on MSCs chondrogenic differentiation in 3-D alginate culture.

Henrionnet C, Wang Y, Roeder E, Gambier N, Galois L, Mainard D, Bensoussan D, Gillet P, Pinzano A

Biomed Mater Eng. 2012;22(4):209-18

French and European regulations for tissue and cell therapy.

Caunday O, Bultel S, Decot V, Bensoussan D, Stoltz JF

Biomed Mater Eng. 2012;22(4):255-9

Introduction to regenerative medicine and tissue engineering.

Stoltz JF, Decot V, Huseltein C, He X, Zhang L, Magdalou J, Li YP, Menu P, Li N, Wang YY, de Isla N, Bensoussan D

Biomed Mater Eng. 2012;22(1-3):3-16

Mesenchymal stem cells derived from Wharton's jelly: comparative phenotype analysis between tissue and in vitro expansion.

Margossian T, Reppel L, Makdissy N, Stoltz JF, Bensoussan D, Huselstein C

Biomed Mater Eng. 2012;22(4):243-54

Thawed autologous peripheral blood stem cells require modified quantification methods for hematopoietic progenitor cell evaluation.

Decot V, Alla F, Latger-Cannard V, Visanica S, Witz B, Stoltz JF, Bensoussan D

Biomed Mater Eng. 2012;22(1-3):57-67

The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation.

D'Aveni M, Aissi-Rothe L, Venard V, Salmon A, Falenga A, Decot V, Virion JM, Wang Y, Clement L, Latger-Cannard V, Tomowiak C, Stoltz JF, Bordigoni P, Bensoussan D

Transpl Immunol. 2011 May;24(4):224-32

Quantitative and qualitative CD4 T cell immune responses related to adenovirus DNAemia in hematopoietic stem cell transplantation.

Guerin-El Khourouj V, Dalle JH, Pedron B, Yakouben K, Bensoussan D, Cordeiro DJ, Peltier L, Ouachee-Chardin M, Baruchel A, Sterkers G

Biol Blood Marrow Transplant. 2011 Apr;17(4):476-85

Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly.

Janda A, Sedlacek P, Honig M, Friedrich W, Champagne M, Matsumoto T, Fischer A, Neven B, Contet A, Bensoussan D, Bordigoni P, Loeb D, Savage W, Jabado N, Bonilla FA, Slatter MA, Davies EG, Gennery AR

Blood. 2010 Sep 30;116(13):2229-36

Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.

Decot V, Voillard L, Latger-Cannard V, Aissi-Rothe L, Perrier P, Stoltz JF, Bensoussan D

Exp Hematol. 2010 May;38(5):351-62

Rapid generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy.

Aissi-Rothe L, Decot V, Venard V, Jeulin H, Salmon A, Clement L, Kennel A, Mathieu C, Dalle JH, Rauser G, Cambouris C, de Carvalho M, Stoltz JF, Bordigoni P, Bensoussan D

J Immunother. 2010 May;33(4):414-24.

Expression of chondrogenic genes by undifferentiated vs. differentiated human mesenchymal stem cells using array technology.

Henrionnet C, Roeder E, Gillet R, Galois L, Bensoussan D, Mainard D, Netter P, Gillet P, Pinzano A

Biomed Mater Eng. 2010 Jan 1;20(3):175-81.

Introduction to tissue engineering and application for cartilage engineering.

de Isla N, Huseltein C, Jessel N, Pinzano A, Decot V, Magdalou J, Bensoussan D, Stoltz JF

Biomed Mater Eng. 2010 Jan 1;20(3):127-33.

Original approach for cartilage tissue engineering with mesenchymal stem cells.

Tritz-Schiavi J, Charif N, Henrionnet C, de Isla N, Bensoussan D, Magdalou J, Benkirane-Jessel N, Stoltz JF, Huselstein C

Biomed Mater Eng. 2010 Jan 1;20(3):167-74.

Autologous bone marrow graft and treatment of delayed and non-unions of long bones: technical aspects.

Galois L, Bensoussan D, Diligent J, Pinzano A, Henrionnet C, Choufani E, Stoltz JF, Mainard D

Biomed Mater Eng. 2009;19(4-5):277-81.

In vitro initial expansion of mesenchymal stem cells is influenced by the culture parameters used in the isolation process.

Chen HH, Decot V, Ouyang JP, Stoltz JF, Bensoussan D, de Isla NG

Biomed Mater Eng. 2009;19(4-5):301-9.

Quantification of residual dimethylsulfoxide after washing cryopreserved stem cells and thawing tissue grafts.

Decot V, Houze P, Stoltz JF, Bensoussan D

Biomed Mater Eng. 2009;19(4-5):293-300.

Regulatory aspects of cellular therapy product in Europe: JACIE accreditation in a processing facility.

Caunday O, Bensoussan D, Decot V, Bordigoni P, Stoltz JF

Biomed Mater Eng. 2009;19(4-5):373-9.

Immune constitution monitoring after PBMC transplantation in complete DiGeorge syndrome: an eight-year follow-up.

Daguindau N, Decot V, Nzietchueng R, Ferrand C, Picard C, Latger-Cannard V, Gregoire MJ, Beri M, Salmon A, Stoltz JF, Bordigoni P, Bensoussan D

Clin Immunol. 2008 Aug;128(2):164-71

Chimerism analysis following nonmyeloablative stem cell transplantation using a new cell subset separation method: Robosep (TM).

Decot V, Latger-Cannard V, Lecompte T, Clement L, Salmon A, Bordigoni P, Stoltz JF, Bensoussan D

Biomed Mater Eng. 2008;18(1 Suppl):S19-26.

Mechanobiology, chondrocyte and cartilage.

Huselstein C, Netter P, de Isla N, Wang Y, Gillet P, Decot V, Muller S, Bensoussan D, Stoltz JF

Biomed Mater Eng. 2008;18(4-5):213-20.

[Persistent thrombocytopenia in a child: morphological examination of blood platelets established the diagnosis of Wiskott-Aldrich syndrome]

Latger-Cannard V, Lacroix F, Devignes J, Salignac S, Bensoussan D, Salmon A, Mansuy L, Bordigoni P, Lecompte T

Ann Biol Clin (Paris). 2008 Jan-Feb;66(1):100-4.

Introduction to endothelial cell biology.

Stoltz JF, Muller S, Kadi A, Decot V, Menu P, Bensoussan D

Clin Hemorheol Microcirc. 2007;37(1-2):5-8.

The WHIM syndrome shows a peculiar dysgranulopoiesis: myelokathexis.

Latger-Cannard V, Bensoussan D, Bordigoni P

Br J Haematol. 2006 Mar;132(6):669.

Cell and tissue engineering and clinical applications: an overview.

Stoltz JF, Bensoussan D, Decot V, Ciree A, Netter P, Gillet P

Biomed Mater Eng. 2006;16(4 Suppl):S3-S18.

Human umbilical vein endothelial cells increase ex vivo expansion of human CD34(+) PBPC through IL-6 secretion.

Li N, Eljaafari A, Bensoussan D, Wang Y, Latger-Cannard V, Serrurier B, Boura C, Kennel A, Stoltz J, Feugier P

Cytotherapy. 2006;8(4):335-42.

Mechanobiology and cartilage engineering: the underlying pathophysiological phenomena.

Stoltz JF, de Isla N, Huselstein C, Bensoussan D, Muller S, Decot V

Biorheology. 2006;43(3-4):171-80.

Osteopetrotic mouse stroma with thrombopoietin, c-kit ligand, and flk-2 ligand supports long-term mobilized CD34+ hematopoiesis in vitro.

Feugier P, Li N, Jo DY, Shieh JH, MacKenzie KL, Lesesve JF, Latger-Cannard V, Bensoussan D, Crystal RG, Rafii S, Stoltz JF, Moore MA

Stem Cells Dev. 2005 Oct;14(5):505-16.

Autologous cell based therapy for treating chronic infarct myocardium.

Tran N, Marie PY, Nloga J, Mascali F, Franken P, Lahoutte T, Li Y, Antunes L, El Jaafari A, Bensoussan D, Stoltz JF, Villemot JP

Clin Hemorheol Microcirc. 2005;33(3):263-8.

From hemorheology to vascular mechanobiology: An overview.

Muller S, Labrador V, Da Isla N, Dumas D, Sun R, Wang X, Wei L, Fawzi-Grancher S, Yang W, Traore M, Boura C, Bensoussan D, Eljaafari A, Stoltz JF

Clin. Hemorheol. Microcirc.. 2004 ;30(3-4):185-200

Spatial distribution of the beta2 integrin (CD11b/CD18) and L-selectin (CD62L) adherence receptors on human neutrophils by Conventional Optical Scanning Microscopy (COSM).

Latger-Cannard V, Dumas D, Bensoussan D, Stoltz JF

Biorheology. 2003;40(1-3):167-72.

T-cell immune constitution after peripheral blood mononuclear cell transplantation in complete DiGeorge syndrome.

Bensoussan D, Le Deist F, Latger-Cannard V, Gregoire MJ, Avinens O, Feugier P, Bourdon V, Andre-Botte C, Schmitt C, Jonveaux P, Eliaou JF, Stoltz JF, Bordigoni P

Br J Haematol. 2002 Jun;117(4):899-906.

Pr BENSOUSSAN Danièle

Fiche personne

Coordonnées

Territoire

Statut

Affiliation

Équipes/plateformes

Publications

Retrouvez aussi